Healthy Adults
Conditions
Brief summary
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).
Interventions
DRUGPF-06882961
Tablets
DRUGAtorvastatin
Tablets
DRUGMidazolam
Syrup
DRUGLevonorgestrel & Ethinyl Estradiol
Tablet
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Part A Only - Healthy male and female participants must be 18 to 65 years of age, inclusive, at the time of signing the ICD (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, physical examination, including blood pressure and pulse rate measurement, standard 12 lead ECG and clinical laboratory tests). * Part B Only - Healthy PM female participants between 40 and 65 years of age, inclusive, at the time of signing the ICD (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, physical examination, including BP and PR measurement, standard 12 lead ECG and clinical laboratory tests). Subjects must be amenorrheic for at least 12 months. Women who are 60 years of age or younger must also have an FSH that is within the laboratory's reference range for PM women. * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * BMI- 20.0 kg/m2 to \<30.0 kg/m2 at Screening. * Stable body weight, defined as \<5 % change (per participant report) for 90 days before Screening. * Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, or any area of intestinal resection, active inflammatory bowel disease or pancreatic insufficiency). * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Known intolerance or hypersensitivity to GLP-1R agonists. * Known hypersensitivity to atorvastatin or midazolam (for participants in Part A), or LE and EE (for participants in Part B). * Personal or family history of MTC or MEN2 or study participants with suspected MTC per the investigator's judgment. * Symptomatic gallbladder disease. * History of major depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years from screening. * Any lifetime history of a suicide attempt. * Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. * Systemic therapy with any of the medications that are moderate or strong CYP3A4/5, CYP2C9 and/or CYP2C19 inhibitors within 28 days or 5 half-lives (whichever is longer) or moderate or strong CYP3A, CYP2C9 and/or CYP2C19 inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention. * Systemic therapy with inhibitors of the BCRP transporter within 28 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. * Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s). * Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). * Known prior participation in a trial involving PF-06882961. * A PHQ-9 score ≥15 obtained at Screening or Day -1 in Study. * Response of yes to question 4 or 5, or on any suicidal behavioral question on the C SSRS at Screening or Day -1 in Study. * A positive urine drug test. * Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. BP should be measured in triplicate and the average of the 3 BP values should be used to determine the participant's eligibility. Note: At screening, the participant's arm circumference should be measured (eg, using a flexible anthropometric tape) at the midpoint of the length of the upper arm and the appropriate cuff selected and used throughout the study. * Screening 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QTcF interval \>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants. * Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary: * HbA1c ≥6.5%. * Aspartate AST or ALT level ≥2 times the ULN. * Total bilirubin level ≥1.5 times the ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN. * TSH \>1.5x the ULN or \<LLN. * Serum calcitonin \> the ULN. * Amylase or lipase \> the ULN. * Fasting blood glucose ≥126 mg/dL. * Fasting C-peptide \<0.8 ng/mL. * eGFR \<70 mL/min/1.73 m2 as calculated by the CKD-EPI equation. * Positive testing for HIV, HepBsAg, or HCVAb. Study participants positive for HCVAb are to be excluded unless known to have been treated with a known curative therapy and negative for HCV RNA. Hepatitis B vaccination is allowed. * A positive SARS-CoV-2 test. * Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening. * History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine). * Current use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. * Known or suspected illicit drug use. * Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing randomization (Day-1). * History of sensitivity to heparin or heparin induced thrombocytopenia if Hep-lock is used for IV blood draw. * Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 | For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period. | Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time. |
| (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 | For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period. | Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time. |
| (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 | For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period. | Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time. |
| (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 | For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period. | Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | From Baseline up to follow-up visit (Days 69-72) in Part A of the study. | Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest. |
| (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | From Baseline up to follow-up visit (Days 72-75) in Part B of the study. | Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest. |
| (Part A) Percentage of Change From Baseline in Body Weight | Percentage of change from Baseline 1: from the last pre-dose measurement in Part A Period 1 (ie, Baseline 1) to Day 2 of Part A Period 8; percentage of Change from the last predose measurement in Part A Period 3 (ie, Baseline 2) to Day 2 of Period 8. | Percentage of changes from Baseline in body weight of the participants were measured. |
| (Part B) Percentage of Change From Baseline in Body Weight | Percentage of Change from Baseline 1:from the last pre-dose measurement in Part B Period 1 (ie, Baseline 1) to Day 2 of Part B Period 8;percentage of Change from the last predose measurement in Part B Period 2 (ie, Baseline 2) to Day 6 of Part B Period 5. | Percentage of changes from Baseline in body weight of the participants were measured. |
| (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | From Baseline up to follow-up visit (Days 69-72) in Part A of the study. | Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex. |
| (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | From Baseline up to follow-up telephone contact (Days 90-97) in Part A of the study. | An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. |
| (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A. | The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts toward imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts or behavior), 4: any suicidal behavior or ideation, suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior). |
| (Part B) Number of Participants With Categorical Scores on the C-SSRS | Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B. | The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts toward imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts or behavior), 4: any suicidal behavior or ideation, suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior). |
| (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A. | The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). |
| (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B. | The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). |
| (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | From Baseline up to follow-up visit (Days 72-75) in Part B of the study. | Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex. |
| (Part B) Number of Participants With TEAE During Part B of the Study | From Baseline up to follow-up telephone contact (Days 94-101) in Part B of the study. | An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. |
| (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | From Baseline up to follow-up visit (Days 69-72) in Part A of the study. | Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria. |
| (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | From Baseline up to follow-up visit (Days 72-75) in Part B of the study. | Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants in Part A Participants underwent Period 1 to 8 and received study interventions as follows: Period 1: atorvastatin 20mg single dose (SD) on Day 1; Period 2: midazolam 5mg SD on Day 1; Period 3: PF-06882961 10mg twice daily (BID) on Days 1-4, 20mg BID on Days 5-8, 40mg BID on Days 9-12, 60mg BID on Days 13-16, 80mg BID on Days 17-20, 100mg BID on Days 21-24, and 120mg BID on Days 25-31; Period 4: PF-06882961 120mg BID+atorvastatin SD on Day 1, PF-06882961 120mg on Days 2-3; Period 5: PF-06882961 120 mg BID+ midazolam SD on Day 1; Period 6: PF-06882961 140 mg BID on Days 1-4, 160 mg BID on Days 5-8, 180 mg BID on Days 9-12, 200 mg BID on Days 13-19; Period 7: PF-06882961 200 mg BID+atorvastatin SD on Day 1, PF-06882961 200 mg BID on Days 2-3; Part 8: PF-06882961 200 mg BID+ midazolam SD on Day 1. | 18 |
| All Participants in Part B Participants underwent Period 1 to 5 and received study interventions as follows: Period 1: oral contraceptive (OC) SD on Day 1; Period 2:PF-06882961 10mg BID on Days 1-4, 20mg BID on Days 5-8, 40mg BID on Days 9-12, 60mg BID on Days 13-16, 80mg BID on Days 17-20, 100mg BID on Days 21-24, and 120mg BID on Days 25-31; Period 3: PF-06882961 120mg BID+OC SD on Day 1, PF-06882961 120mg on Days 2-5; Period 4: PF-06882961 140 mg BID on Days 1-4, 160 mg BID on Days 5-8, 180 mg BID on Days 9-12, 200 mg BID on Days 13-19; Period 5: PF-06882961 200 mg BID+OC SD on Day 1, PF-06882961 200 mg BID on Days 2-5. | 17 |
| Total | 35 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A Period 2 - Treatment | Physician Decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A Period 3 - Treatment | Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A Period 3 - Treatment | Physician Decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A Period 3 - Treatment | Withdrawal by Subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A Period 6 - Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A Period 8 - Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Part B Period 1 - Treatment | Protocol Violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Part B Period 2 - Follow-Up | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Part B Period 2 - Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Part B Period 3 - Follow-Up | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Part B Period 3 - Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Part B Period 4 - Follow-Up | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Part B Period 4 - Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Part B Period 4 - Treatment | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| Age, Continuous Mean (SD) | 41.2 Years STANDARD_DEVIATION 11.63 | 54.5 Years STANDARD_DEVIATION 4.16 | 47.7 Years STANDARD_DEVIATION 11.01 |
| Age, Customized 18-25 Years | 2 Participants | 0 Participants | 2 Participants |
| Age, Customized <18 Years | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 26-35 Years | 4 Participants | 0 Participants | 4 Participants |
| Age, Customized 36-45 Years | 4 Participants | 0 Participants | 4 Participants |
| Age, Customized >45 Years | 8 Participants | 17 Participants | 25 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Black or African American | 2 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 8 Participants | 9 Participants | 17 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 10 Participants | 8 Participants | 18 Participants |
| Race/Ethnicity, Customized White | 15 Participants | 14 Participants | 29 Participants |
| Sex: Female, Male Female | 2 Participants | 17 Participants | 19 Participants |
| Sex: Female, Male Male | 16 Participants | 0 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 18 | 0 / 18 | 0 / 17 | 0 / 13 | 0 / 13 | 0 / 13 | 0 / 5 | 0 / 6 | 0 / 17 | 0 / 16 | 0 / 14 | 0 / 12 | 0 / 9 |
| other Total, other adverse events | 2 / 18 | 3 / 18 | 13 / 17 | 5 / 13 | 4 / 13 | 12 / 13 | 5 / 5 | 2 / 6 | 5 / 17 | 15 / 16 | 7 / 14 | 12 / 12 | 7 / 9 |
| serious Total, serious adverse events | 0 / 18 | 0 / 18 | 0 / 17 | 0 / 13 | 0 / 13 | 0 / 13 | 0 / 5 | 0 / 6 | 0 / 17 | 0 / 16 | 0 / 14 | 0 / 12 | 0 / 9 |
Outcome results
Primary
(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7
Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period.
Population: Only participants with evaluable results for the pharmacokinetic (PK) parameter were included in the analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 | 32.27 nanogram*hour/milliliter (ng*hr/mL) | Geometric Coefficient of Variation 41 |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 | 46.94 nanogram*hour/milliliter (ng*hr/mL) | Geometric Coefficient of Variation 72 |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 | 54.43 nanogram*hour/milliliter (ng*hr/mL) | Geometric Coefficient of Variation 22 |
Primary
(Part A) AUCinf of Midazolam in Periods 2, 5, and 8
Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period.
Population: Only participants with evaluable results for the PK parameter were included in the analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 | 70.53 ng*hr/mL | Geometric Coefficient of Variation 32 |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 | 58.81 ng*hr/mL | Geometric Coefficient of Variation 40 |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 | 49.78 ng*hr/mL | Geometric Coefficient of Variation 22 |
Primary
(Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5
Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period.
Population: Only participants with evaluable results for the PK parameter were included in the analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 | 772.1 pg*hr/mL | Geometric Coefficient of Variation 41 |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 | 723.5 pg*hr/mL | Geometric Coefficient of Variation 24 |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 | 604.4 pg*hr/mL | Geometric Coefficient of Variation 33 |
90% CI: [92.56, 117.89]Mixed Models Analysis
90% CI: [81.05, 106.19]Mixed Models Analysis
Primary
(Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5
Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period.
Population: Only participants with evaluable results for the PK parameter were included in the analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 | 48800 picogram*hour/milliliter (pg*hr/mL) | Geometric Coefficient of Variation 42 |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 | 62330 picogram*hour/milliliter (pg*hr/mL) | Geometric Coefficient of Variation 61 |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 | 66490 picogram*hour/milliliter (pg*hr/mL) | Geometric Coefficient of Variation 57 |
90% CI: [106.96, 140.25]Mixed Models Analysis
90% CI: [122.64, 168.68]Mixed Models Analysis
Secondary
(Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts toward imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts or behavior), 4: any suicidal behavior or ideation, suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable C-SSRS results were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 1 Day -1 / Atorvastatin 20 mg | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow Up (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 1 Day -1 / Atorvastatin 20 mg Past 12 Months | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg (Since Last Visit) | 0 Participants |
Secondary
(Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable PHQ-9 results were analyzed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Nearly Every Day | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Not At All | 7 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Nearly Every Day | 3 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Not At All | 6 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Not At All | 6 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead | Not At All | 6 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up | Not At All | 14 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Not At All | 18 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Not At All | 6 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating | Not At All | 5 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself | Not At All | 6 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
Secondary
(Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 15 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 16 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 2 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 5 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 12 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 6 Participants |
Secondary
(Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From Baseline up to follow-up telephone contact (Days 90-97) in Part A of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 3 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 2 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 13 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 5 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 4 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 7 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 12 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 4 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 5 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants discontinued study drug due to AE and continue study | 1 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with adverse events | 2 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study | Participants with serious adverse events | 0 Participants |
Secondary
(Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF 30 msec < change <=60 msec | 1 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study | QTcF value >500 msec | 0 Participants |
Secondary
(Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study
Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 2 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 2 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 3 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 2 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg increase | 1 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine systolic blood pressure (SBP) value <90 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study | Pulse rate value >120 bpm | 0 Participants |
Secondary
(Part A) Percentage of Change From Baseline in Body Weight
Percentage of changes from Baseline in body weight of the participants were measured.
Time frame: Percentage of change from Baseline 1: from the last pre-dose measurement in Part A Period 1 (ie, Baseline 1) to Day 2 of Part A Period 8; percentage of Change from the last predose measurement in Part A Period 3 (ie, Baseline 2) to Day 2 of Period 8.
Population: All participants who were randomly assigned to study intervention and had at least 1 dose of study intervention, and with evaluable body weight measurement were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Percentage of Change From Baseline in Body Weight | Baseline 1 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg | -9.04 percentage | Standard Deviation 3.539 |
| Atorvastatin 20 mg (Part A Period 1) | (Part A) Percentage of Change From Baseline in Body Weight | Baseline 2 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg | -9.30 percentage | Standard Deviation 4.159 |
Secondary
(Part B) Number of Participants With Categorical Scores on the C-SSRS
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts toward imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts or behavior), 4: any suicidal behavior or ideation, suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable C-SSRS results were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE (Past 12 months) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit) | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the C-SSRS | Follow Up (Since Last Visit) | 0 Participants |
Secondary
(Part B) Number of Participants With Categorical Scores on the PHQ-9
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable PHQ-9 results were analyzed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Not At All | 17 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Several Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating | Not At All | 7 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating | Not At All | 7 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Not At All | 8 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Little Interest/Pleasure in Things | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Down Depressed or Hopeless | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Falling or Staying Asleep | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Tired or Little Energy | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Tired or Little Energy | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Poor Appetite or Overeating | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Bad About Yourself | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Concentrating on Things | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Moving Slowly or Fidgety/Restless | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Thoughts You Be Better Off Dead | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Not At All | 13 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | Several Days | 3 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy | Nearly Every Day | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | More Than Half The Days | 3 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating | Nearly Every Day | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things | Not At All | 14 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | More Than Half The Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Not At All | 15 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Not At All | 11 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Not At All | 10 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Not At All | 9 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating | Nearly Every Day | 2 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead | Not At All | 12 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things | Several Days | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Categorical Scores on the PHQ-9 | Follow Up / Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
Secondary
(Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 17 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 16 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 12 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 9 Participants |
Secondary
(Part B) Number of Participants With TEAE During Part B of the Study
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From Baseline up to follow-up telephone contact (Days 94-101) in Part B of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with severe adverse events | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued from study due to AEs | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with serious adverse events | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with adverse events | 5 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued study drug due to AE and continue study | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with dose reduced or temporary discontinuation due to AE | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with adverse events | 15 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with adverse events | 7 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued study drug due to AE and continue study | 2 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued study drug due to AE and continue study | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with dose reduced or temporary discontinuation due to AE | 2 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with adverse events | 12 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with severe adverse events | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with dose reduced or temporary discontinuation due to AE | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued from study due to AEs | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants discontinued study drug due to AE and continue study | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with serious adverse events | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With TEAE During Part B of the Study | Participants with adverse events | 7 Participants |
Secondary
(Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF change >60 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval value >=300 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval %change >=25/50% msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval value >= 140 msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval %change >=50% msec | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 450 msec < value <=480 msec | 1 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF change >60 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF value >500 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval %change >=50% msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval %change >=25/50% msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 30 msec < change <=60 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QRS interval value >= 140 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | PR interval value >=300 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 480 msec < value <=500 msec | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study | QTcF 450 msec < value <=480 msec | 0 Participants |
Secondary
(Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study
Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Population: All participants randomly assigned to study intervention and who had at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP value <50 mm Hg | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value <40 bpm | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP value <90 mm Hg | 0 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg decrease | 3 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg decrease | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg decrease | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP value <50 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP value <90 mm Hg | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP value <50 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value >120 bpm | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Pulse rate value <40 bpm | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP change >=30 mm Hg increase | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine SBP value <90 mm Hg | 0 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg decrease | 1 Participants |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study | Supine DBP >= 20 mm Hg increase | 0 Participants |
Secondary
(Part B) Percentage of Change From Baseline in Body Weight
Percentage of changes from Baseline in body weight of the participants were measured.
Time frame: Percentage of Change from Baseline 1:from the last pre-dose measurement in Part B Period 1 (ie, Baseline 1) to Day 2 of Part B Period 8;percentage of Change from the last predose measurement in Part B Period 2 (ie, Baseline 2) to Day 6 of Part B Period 5.
Population: All participants who were randomly assigned to study intervention and had at least 1 dose of study intervention, and with evaluable body weight measurement were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Percentage of Change From Baseline in Body Weight | Baseline 1 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE | -8.77 percentage | Standard Deviation 2.19 |
| Atorvastatin 20 mg (Part A Period 1) | (Part B) Percentage of Change From Baseline in Body Weight | Baseline 2 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE | -5.40 percentage | Standard Deviation 1.503 |